Digitalis Ventures backs founders solving critical problems in health. Our areas of interest are determined by an ongoing process of defining, exploring, and understanding major unmet medical and healthcare needs. We seek solutions inspired by an engineering mindset and informed by deep technical, financial, and domain expertise.
We invest in early-stage companies across the healthcare ecosystem with the goal of supporting them throughout their development. We also create companies focused on bringing about a healthier world through the life sciences and health technology.
In all of our endeavors, the expertise of our multidisciplinary team — combined with the expansive network of entrepreneurs, experts, and academic institutions with whom we have worked over the years — allows us to forge deep partnerships that lead to enduring solutions.
The Digitalis plant is the natural source of cardioactive steroid glycosides widely used in the treatment of heart disease since the 1700s. Dr. Thomas W. Smith, the father of our founding partner, began his career as a physician-scientist at Harvard by developing a novel radioimmunoassay to enable the safe administration of digitalis. Dr. Smith’s subsequent research program touched on many themes—the health benefits of nature-derived compounds, the importance of measurement science in therapeutic development, rational design in drug discovery, among many others that continue to resonate with our group today. Beyond his research, Dr. Smith was a renowned clinician and beloved mentor to a generation of academic cardiologists. Our name reflects our ongoing commitment to this legacy of both scientific innovation and human connection.